Immunotherapy shows promise in Phase III neuroblastoma trial.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology*; D017326:Clinical Trials, Phase III as Topic; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D009447:Neuroblastoma / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D005732:Gangliosides; C019403:ganglioside, GD2